Business
Bell Potter thinks the Mesoblast (ASX:MSB) share price can run higher
Well, 2020 was yet another rollercoaster ride for the Mesoblast Limited (ASX: MSB) share price, as good and bad news pushed and pulled on the company’s shares.
The latest piece of disappointing news from Mesoblast was on its remestemcel-L product. This is used for ventilator dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
The Mesoblast share price spiralled 45% lower when the trial was reported to be unlikely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment.
Despite the trial shortcomings, Bell Potter maintained a speculative buy recommendation on Mesoblast shares on 23 December 2020. The broker updated its Mesoblast share…
-
Noosa News21 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General22 hours agoMinjee Lee rallies after third-round meltdown to share fifth place at LA Championship
-
General15 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General18 hours agoReason v magical climate thinking – voters have no choice